Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma

Cancer Chemother Pharmacol. 2018 Jan;81(1):223. doi: 10.1007/s00280-017-3448-9.

Michael A Badruddoja^{1

2}, Marjorie Pazzi³, Abhay Sanan³, Kurt Schroeder³, Kevin Kuzma⁴, Thomas Norton³, Thomas Scully^{3

5}, Daruka Mahadevan⁶, Michael Malek Ahmadi^{3

4}

¹ Center for Neurosciences, 2450 E River Rd, Tucson, AZ, 85718, USA. badru001@neurotucson.com.
² Department of Radiation Oncology, Banner University Medical Center, 1501 N. Campbell Avenue, Tucson, AZ, 85724, USA. badru001@neurotucson.com.
³ Center for Neurosciences, 2450 E River Rd, Tucson, AZ, 85718, USA.
⁴ Genentech, Inc., DNA Way, South San Francisco, CA, 94080, USA.
⁵ Northwest Neurospecialists, 5860 N. La Cholla Blvd. Suite 100, Tucson, AZ, 85741, USA.
⁶ University of Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson, AZ, 85724, USA. dmahadevan@uacc.arizona.edu.

No abstract available

Publication types